Featured Research

from universities, journals, and other organizations

Cigarette smoke may contribute to lung inflammation through a new chemical pathway

Date:
September 3, 2010
Source:
University of Alabama at Birmingham
Summary:
Cigarette smoke shuts off a key enzyme in airways that regulates the body's response to inflammation, according to new findings. Researchers say smoke inhibits the enzyme, called Leukotriene A4 Hydrolase (LTA4H), causing it to fail in its job of shutting down white blood cells following a successful response to inflammation.

New research shows that cigarette smoke shuts off a key enzyme in airways that regulates the body's response to inflammation.
Credit: iStockphoto

Cigarette smoke shuts off a key enzyme in airways that regulates the body's response to inflammation, according to findings from the University of Alabama at Birmingham published online in Science Express.

The UAB researchers say smoke inhibits the enzyme, called Leukotriene A4 Hydrolase (LTA4H), causing it to fail in its job of shutting down white blood cells following a successful response to inflammation.

The team says the research study identified a previously unknown substrate of LTA4H called proline-glycine-proline (PGP). In a normal response to inflammation, PGP's role is to recruit neutrophils -- white blood cells -- that rush to the scene and attack the cause of the inflammation. When the job is over, LTA4H steps in to shut off PGP, in turn halting the recruitment of neutrophils and ending the body's defensive stand.

"We found, however, that cigarette smoke inhibited LTA4H, preventing it from shutting down PGP," said J. Edwin Blalock, Ph.D., senior author and professor in the UAB Division of Pulmonary, Allergy and Critical Care Medicine. "A continued presence of PGP means a continued response of neutrophils, a never-ending cycle that supports chronic inflammation."

Blalock said PGP is a biomarker for several lung diseases that feature chronic inflammation, such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis.

The study also details a dual role played by LTA4H in suppressing or encouraging inflammation. When contained within a cell, LTA4H has a pro-inflammatory job, generating an agent know as Leukotriene B4 (LTB4), which, much like PGP, calls in the neutrophils when required. However, when LTA4H is found outside of the cell (when the cell it resides in dies, for example) its role switches to an anti-inflammatory one, as it works to suppress PGP and end the body's inflammatory response.

"This dual role was poorly understood until we identified PGP," said Blalock. "This could have important ramifications for the design of new anti-inflammatory drugs that target LTA4H."

Blalock said that because too much LTB4 can contribute to chronic inflammation, pharmaceutical manufacturers are examining potential drugs to inhibit LTA4H, thus reducing the amount of LTB4. Blalock said he believes that approach needs revision.

"Drugs are in design that would reduce LTB4 by shutting down LTA4H," he said. "But we now know that LTA4H has a beneficial role to play in the reduction of PGP.

"While inhibiting LTB4 might be a good thing, to simultaneously block LTA4H's ability to degrade PGP defeats the purpose, and may make the situation worse."

This study was supported by grants from the National Heart, Lung and Blood Institute, one of the National Institutes of Health.

Blalock collaborated with Robert Snelgrove, Ph.D., of the Imperial College London, along with colleagues at the University of Montevallo (Montevallo, Ala.), the Birmingham Veterans Affairs Medical Center and the UAB Lung Health Center, Gregory Fleming James Cystic Fibrosis Center and Department of Pediatrics.


Story Source:

The above story is based on materials provided by University of Alabama at Birmingham. Note: Materials may be edited for content and length.


Journal Reference:

  1. Robert J. Snelgrove, Patricia L. Jackson, Matthew T. Hardison, Brett D. Noerager, Andrew Kinloch, Amit Gaggar, Suresh Shastry, Steven M. Rowe, Yun M. Shim, Tracy Hussell, and J. Edwin Blalock. A Critical Role for LTA4H in Limiting Chronic Pulmonary Neutrophilic Inflammation. Science, 2010; DOI: 10.1126/science.1190594

Cite This Page:

University of Alabama at Birmingham. "Cigarette smoke may contribute to lung inflammation through a new chemical pathway." ScienceDaily. ScienceDaily, 3 September 2010. <www.sciencedaily.com/releases/2010/09/100902173259.htm>.
University of Alabama at Birmingham. (2010, September 3). Cigarette smoke may contribute to lung inflammation through a new chemical pathway. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/09/100902173259.htm
University of Alabama at Birmingham. "Cigarette smoke may contribute to lung inflammation through a new chemical pathway." ScienceDaily. www.sciencedaily.com/releases/2010/09/100902173259.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins